Briefly Bio Secures $1.2M to Tackle Science's Reproducibility Crisis

The London-based startup uses AI to standardize lab documentation, enhancing collaboration and reducing research inefficiencies.

Over 50% of preclinical research experiments fail to reproduce, costing the industry $50 billion annually.
Briefly Bio's platform converts complex lab protocols into structured, consistent formats using large language models.
The software includes an AI copilot to identify errors and fill in missing parameters in experimental methods.
Early adopters include biotech and pharmaceutical companies, with plans for a public version to facilitate open sharing.
Investors in the pre-seed round include Compound VC, NP Hard, Tiny VC, and various angel investors.